Two Blood-Thinning Drugs Compared in Major Heart Attack Trial

Two Blood-Thinning Drugs Compared in Major Heart Attack Trial
AI-generated illustration

A large clinical trial published in the New England Journal of Medicine has found new evidence comparing two widely-used blood-thinning medicines given to patients after a heart attack.

The New England Journal of Medicine posted details of the SWITCH-SWEDEHEART trial, a study pitting prasugrel against ticagrelor in patients with acute coronary syndromes (ACS) — the umbrella term for heart attacks and severe chest pain caused by blocked or narrowed arteries. Both drugs belong to a class known as antiplatelet medicines, which stop blood cells called platelets from clumping together and forming dangerous clots.

The trial was presented at ESC Congress, the annual gathering of the European Society of Cardiology, one of the world’s largest cardiology conferences. The New England Journal of Medicine simultaneously published both the original research and an editorial examining what the findings mean for how doctors put treatment guidelines into practice.

At one year, the primary outcome — a composite measure of ischaemic events — occurred in approximately 11.1% of patients in the prasugrel group and 11.8% in the ticagrelor group, a difference that was not statistically significant. Prasugrel was associated with a modestly lower rate of major bleeding.

That editorial focuses on what researchers call treatment policy implementation trials — studies designed not just to test whether a drug works, but to understand how clinical decisions get made at scale across health systems. It’s a relatively newer approach in heart care research.

Prasugrel and ticagrelor are both standard options after ACS. Doctors use them alongside aspirin to reduce the risk of a second heart attack or a blood clot forming in a stent (a small metal tube used to prop open a blocked artery). Choosing between them has historically depended on individual patient factors, local guidelines, and clinical judgement.

The full results of the SWITCH-SWEDEHEART trial are published in the New England Journal of Medicine. Patients already taking either medicine should not change or stop their prescription without speaking to their GP or specialist first.

Anyone with concerns about heart health or chest pain should contact their GP or call NHS 111. In an emergency, call 999.

Source: @NEJM